Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease

Bibliographic Details
Main Authors:	Stergios A. Polyzos, Jannis Kountouras
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
by: Chunlong Liu, et al.
Published: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
by: Kaleb Tesfai, et al.
Published: (2026)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Soroor Owrangi, et al.
Published: (2024)

Prevalence and Predictors of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States
by: Sheila L. Noon, et al.
Published: (2025)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
by: Jannis Kountouras, et al.
Published: (2025)

Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality
by: Donghee Kim, et al.
Published: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
by: Donghee Kim, et al.
Published: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
by: Luis Calzadilla Bertot, et al.
Published: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Steatotic Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria
by: Julie Bonn, et al.
Published: (2025)

Extracellular Vesicles miRNome Profiling Reveals miRNAs Engagement in Dysfunctional Lipid Metabolism, Chronic Inflammation and Liver Damage in Subjects With Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Gian Paolo Caviglia, et al.
Published: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
by: Jia‐Yong Su, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
by: C. C. Mark Cheah, et al.
Published: (2025)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
by: Jannis Kountouras, et al.
Published: (2024)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
by: Isabella Lurje, et al.
Published: (2025)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
by: Yee Hui Yeo, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply
by: Xiao‐Dong Zhou, et al.
Published: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Shinya Yokoyama, et al.
Published: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
by: Kaleb Tesfai, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
by: Karen Cheuk‐Ying Ho, et al.
Published: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
by: Jee‐Fu Huang, et al.
Published: (2026)

Editorial: Time to Genotype—Genetic Risk and Prognosis in Steatotic Liver Disease
by: Rosellina M. Mancina, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
by: Sheila L. Noon, et al.
Published: (2025)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
by: Kelly Torosian, et al.
Published: (2025)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
by: Jannis Kountouras, et al.
Published: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
by: Johnny Yau‐Cheung Chang, et al.
Published: (2025)

Editorial: Two Common Risks, One Greater Harm—Diabetes and Alcohol in Steatotic Liver Disease
by: Stine Johansen, et al.
Published: (2026)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
by: Takao Miwa, et al.
Published: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
by: Xinglin Li, et al.
Published: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
by: Muhammad Osama, et al.
Published: (2024)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
by: Raj Vuppalanchi, et al.
Published: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
by: Ryan Yanzhe Lim, et al.
Published: (2026)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
by: Matheus Souza, et al.
Published: (2026)

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
by: Zhenqiu Liu, et al.
Published: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
by: Rong‐Xiang Ng, et al.
Published: (2025)

Similar Items

Similar Items